Information regarding the cost of Xofluza without insurance is not available in the provided text.
How does Xofluza work?
Xofluza, also known as baloxavir marboxil, is an antiviral medication prescribed to treat influenza. It works by inhibiting the cap-dependent endonuclease of the influenza virus polymerase acidic protein [1]. This mechanism is distinct from older influenza medications that target viral neuraminidase [2]. By blocking this viral enzyme, Xofluza prevents the virus from replicating within the body [1].
When was Xofluza approved?
The U.S. Food and Drug Administration (FDA) approved Xofluza for the treatment of acute uncomplicated influenza in individuals 12 years of age and older on October 24, 2018 [3].
How is Xofluza taken?
Xofluza is typically administered as a single oral dose [1]. The recommended dosage for eligible patients is 40 mg (two 20 mg tablets) taken once [4].
How does Xofluza compare to other flu treatments?
Xofluza's novel mechanism of action, targeting viral endonuclease, differentiates it from older influenza treatments like oseltamivir (Tamiflu) and zanamivir (Relenza), which inhibit neuraminidase [2]. Studies have shown Xofluza to be effective in reducing the duration of flu symptoms [1].
What are the potential side effects of Xofluza?
Common side effects reported with Xofluza include diarrhea, bronchitis, nausea, vomiting, and sinus headaches [3].
Are there any precautions when taking Xofluza?
Patients should inform their healthcare provider about any pre-existing medical conditions, especially if they have kidney disease or are pregnant or breastfeeding [4]. Co-administration with certain other medications may also require caution [4].
What is the patent situation for Xofluza?
Information regarding Xofluza's patent status and expiry dates is not available in the provided text. DrugPatentWatch.com tracks patents for numerous medications, including antivirals [5].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210401s000lbl.pdf
[2] https://www.nejm.org/doi/full/10.1056/NEJMoa1713553
[3] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-xofluza-baloxavir-marboxil-treat-influenza-a-and-b
[4] https://www.xofluza.com/
[5] https://drugpatentwatch.com/